KENILWORTH, N.J.–(BUSINESS WIRE) July 31, 2019 –Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as…Original Article
You may also like
Apellis Announces U.S. FDA Approval of the Empaveli...
FDA Approves Technegas (Technetium Tc 99-m Labeled...
FDA Approves Rivfloza (nedosiran) for the Treatment of...
FDA Approves Tofidence (tocilizumab-bavi), a...
FDA Approves Exxua (gepirone) for the Treatment of...
FDA Approves Pombiliti (cipaglucosidase alfa-atga) +...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.